◀ Back to PPARA

CCL2 — PPARA

Text-mined interactions from Literome

Lee et al., Neuroreport 2005 (Inflammation) : PPAR-alpha activators also suppressed lipopolysaccharide stimulated tumor necrosis factor-alpha and monocyte chemoattractant protein-1 transcription and release
Dragomir et al., Vascul Pharmacol 2006 : Aspirin and PPAR-alpha activators inhibit monocyte chemoattractant protein-1 expression induced by high glucose concentration in human endothelial cells ... Together, the findings indicate that in endothelial cells aspirin and PPAR-alpha activators reduce the high glucose increased expression of MCP-1 by a mechanism that includes the inhibition of reactive oxygen species, and decrease of AP-1 and NF-kB activation
Taketa et al., J Biol Chem 2008 (Atherosclerosis...) : Interestingly, specific inhibition of PPARalpha and PPARgamma suppressed Ox-LDL induced ATP binding cassette transporter A1 mRNA expression and enhanced Ox-LDL induced monocyte chemoattractant protein-1 mRNA expression
Huang et al., J Neurochem 2008 : Importantly, increased PPAR activity attenuated induction of IL-1beta, tumor necrosis factor-alpha, CCL2 , and E-selectin in hCMEC/D3 cells co-cultured with HIV-1 infected Jurkat cells
Antonelli et al., Exp Cell Res 2011 (Graves Disease) : The role of PPARa and PPAR? activation on CXCL10 and CCL2 secretion was tested in Graves ' disease ( GD ) and control primary thyrocytes stimulated with interferon ( IFN ) ? and tumor necrosis factor ( TNF ) a. IFN? stimulated both CXCL10 and CCL2 secretion in primary GD and control thyrocytes
Sauter et al., Mediators Inflamm 2012 : The present study was designed to assess the effect of the peroxisome proliferator activated receptor-gamma- ( PPAR?- ) activator rosiglitazone on the mesothelial MCP-1 expression and release